Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. is set to hold a Q3 2025 performance briefing on November 18, 2025, to enhance investor understanding of its operational performance and development strategy [3][4]. Group 1: Meeting Details - The performance briefing will take place on November 18, 2025, from 15:30 to 16:30 [4]. - The meeting will be conducted online via the "Value Online" platform [4]. - Key personnel attending the meeting include Chairman Lin Hongli, Independent Director Chen Shengqun, CFO Lin Xiusong, and Board Secretary Huang Mingxiong [4]. Group 2: Investor Participation - Investors can submit questions before the meeting until November 18, 2025, through a designated website or by scanning a QR code [2][5]. - During the briefing, the company will address common investor concerns within the scope of information disclosure [2][5]. Group 3: Contact Information - For inquiries, investors can contact Huang Mingxiong or Wang Yu via phone, fax, or email [6].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 证券代码：603168 证券简称：莎普爱思 公告编号：临2025-066 浙江莎普爱思药业股份有限公司 关于召开2025年三季度业绩说明会的公告 公司已于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）披 露了《浙江莎普爱思药业股份有限公司 2025 年三季度报告》。为便于广大投资 者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2025 年 11 月 18 日（星期二）15:30-16:30 在"价值在线"（www.ir-online.cn）举办浙江莎普 会议召开时间：2025 年 11 月 18 日（星期二）15:30-16:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 11 月 18 日 前 访 问 网 址 https://eseb.cn/1sTxE55zVx6 或使用微信扫描下方小程 ...

Core Viewpoint - On November 10, a total of 10 listed companies will have their restricted shares unlocked, with a total market value of approximately 9.248 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Antai Technology (Stock Code: 000969) with 488,400 shares from equity incentive restrictions - Fenghuo Communication (Stock Code: 600498) with 18.4 million shares from equity incentive restrictions - Supor (Stock Code: 002032) with 604,000 shares from equity incentive restrictions - Shapuaisi (Stock Code: 603168) with 49.9215 million shares from A-share issuance to legal person placement - Zhujiang Piano (Stock Code: 002678) with 152,700 shares from equity incentive restrictions - Chuangli Group (Stock Code: 603012) with 32,400 shares from equity incentive restrictions - Xianle Health (Stock Code: 300791) with 31,950 shares from equity incentive restrictions - Southeast Electronics (Stock Code: 301359) with 57.9959 million shares from pre-issue share restrictions - Lihang Technology (Stock Code: 603261) with 40,740 shares from equity incentive restrictions - Youyan Silicon (Stock Code: 688432) with 740 million shares [1]

Group 1 - The State Council will hold a press conference to discuss the acceleration of scenario cultivation and the large-scale application of new scenarios [2] - Domestic oil prices are expected to rise for the seventh time this year, with the new pricing window opening on November 10 [3] - The HPV vaccine will be included in the national immunization program starting November 10, 2025, for girls born after November 10, 2011 [4] Group 2 - A total of 13 companies will have their restricted shares unlocked today, with a combined market value of 12.143 billion yuan [5] - The companies with the largest number of unlocked shares include Youyan Silicon, Shapuaisi, and Southeast Electronics, with respective unlock volumes of 74 million shares, 4.99215 million shares, and 3.25328 million shares [5] - The companies with the highest market value of unlocked shares are Youyan Silicon, Southeast Electronics, and Shapuaisi, with respective values of 9.991 billion yuan, 677 million yuan, and 403 million yuan [5]

Core Viewpoint - On November 10, a total of 13 companies had their restricted shares unlocked, with a total unlock volume of 846 million shares, amounting to a market value of 12.143 billion yuan based on the latest closing prices [1] Summary by Category Unlock Volume - Three companies had unlock volumes exceeding 10 million shares: Youyan Silicon (74 million shares), Shapuaisi (4.99215 million shares), and Southeast Electronics (3.25328 million shares) [1] Unlock Market Value - The three companies with the highest unlock market values were Youyan Silicon (9.991 billion yuan), Southeast Electronics (677 million yuan), and Shapuaisi (403 million yuan) [1]

Core Viewpoint - On November 10, a total of 13 companies had their restricted shares unlocked, with a total unlock volume of 846 million shares, amounting to a market value of 12.143 billion yuan based on the latest closing price [1] Summary by Category Unlock Volume - Three companies had unlock volumes exceeding 10 million shares: Aoyang Silicon, Shapuaisi, and Southeast Electronics, with unlock volumes of 740 million shares, 49.9215 million shares, and 32.5328 million shares respectively [1] Unlock Market Value - The three companies with the highest unlock market value were Aoyang Silicon, Southeast Electronics, and Shapuaisi, with unlock market values of 9.991 billion yuan, 677 million yuan, and 403 million yuan respectively [1] Unlock Ratio - The three companies with the highest unlock ratio relative to total share capital were Aoyang Silicon, Southeast Electronics, and Shapuaisi, with unlock ratios of 59.32%, 27.07%, and 13.34% respectively [1]

Core Points - The company announced that the restricted shares to be listed for circulation are from a non-public offering, totaling 49.9215 million shares, which accounts for 13.34% of the company's total share capital [1] - The listing date for these shares is set for November 10, 2025, with the issuance targets being Shanghai Yanghe Industrial Co., Ltd. and Lin Hongyuan [1] - The company received approval for the non-public offering in November 2021, and the new shares were registered in November 2022, with a lock-up period of 36 months [1] - Due to changes from incentive plan share grants and repurchases, the current total share capital stands at 374,126,505 shares [1] - The sponsor institution has no objections to the listing of these restricted shares [1]

证券代码：603168 证券简称：莎普爱思 公告编号：2025-065 浙江莎普爱思药业股份有限公司 非公开发行股票限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 责任公司上海分公司办理完毕登记托管相关事宜，中国证券登记结算有限责任公 司上海分公司出具了《证券变更登记证明》。 本次股票上市类型为非公开发行股份；股票认购方式为网下，上市股数为 49,921,506股。 本次股票上市流通总数为49,921,506股。 本次股票上市流通日期为2025 年 11 月 10 日。 一、本次限售股上市类型 浙江莎普爱思药业股份有限公司（以下简称"公司"）本次上市流通的限售股 类型为非公开发行股票限售股。 （一）非公开发行股票核准情况 2021年11月15日，中国证券监督管理委员会出具的《关于核准浙江莎普爱思 药业股份有限公司非公开发行股票的批复》（证监许可[2021]3633号），核准公司非 公开发行股票。 （二）发行股票登记情况 本次发行新增49,921,506股股份已于2022年11月8日在中 ...

申万宏源证券承销保荐有限责任公司 关于浙江莎普爱思药业股份有限公司 非公开发行股票限售股上市流通的核查意见 （二）发行股票登记情况 本次发行新增49,921,506股股份已于2022年11月8日在中国证券登记结算有 限责任公司上海分公司办理完毕登记托管相关事宜，中国证券登记结算有限责任 公司上海分公司出具了《证券变更登记证明》。 （三）锁定期安排 | 序号 | 发行对象名称 | 认购股数（股） | 限售期（月） | | | --- | --- | --- | --- | --- | | 1 | 上海养和实业有限公司 | 47,095,761 | | 36 | | 2 | 林弘远 | 2,825,745 | | 36 | 二、本次限售股形成后至今公司股本数量变化情况 本次非公开发行股票完成后，公司总股本由发行前的322,592,499股增加至发 行后的372,514,005股。 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"，"保 荐机构"）作为浙江莎普爱思药业股份有限公司（以下简称"莎普爱思"或"公司"） 非公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证 券交易所股票上市 ...

Core Viewpoint - The company has announced significant updates regarding its financial performance, corporate governance, and product approvals, which may impact its market position and investor interest. Financial Performance - The third-quarter financial report for 2025 has been prepared but is not audited [3] - The report includes key financial data and indicators, although specific figures are not disclosed in the provided documents [3][4] Corporate Governance - The company plans to repurchase and cancel 1,798,500 restricted shares due to certain employees leaving and performance not meeting targets, reducing total shares from 375,925,005 to 374,126,505 [7][8] - A board meeting was held on October 30, 2025, where several resolutions were passed, including the approval of the third-quarter report and the election of board members [34][36][41] Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for November 19, 2025, with both on-site and online voting options available [10][12] - Shareholders must register to attend the meeting, with specific requirements outlined for both corporate and individual shareholders [20][25] Product Approval - The company received approval for a supplementary application for sodium hyaluronate eye drops, which will enhance its product line and market competitiveness [32][33] - The total R&D investment for this project is approximately 6.5889 million RMB [32]